Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
- Global & Regional Combination Cancer Immunotherapy Market Insight Till 2028
- Combination Cancer Immunotherapy Market Opportunity: > USD 15 Billion
- Combination Cancer Immunotherapy Market By 15 Different Cancers
- Insight On Clinically & Commercially Approved Cancer Immunotherapy Combinations
- Patent, Price & Dosage Analysis On Approved Combination Drugs
- Global & Regional Sales Insights On Approved Combination Drugs Till 2028
- Insight on 600 Combination Cancer Immunotherapy Drugs In Clinical Trials
- Insight on 45 Combination Cancer Immunotherapy Drugs Commercially Approved In Market
- Clinical Trials & Patent Insight By Company, Country, Indication & Phase
In recent years, combining two or more therapeutic agents has become a cornerstone of cancer therapy. The combinatory effect of anti-cancer drugs targets key pathways in a characteristically synergistic or additive manner, which potentially reduces drug resistance, tumor growth and metastatic potential. Till date, a cocktail of targeted therapeutics have been approved in combination with conventional cancer therapies or other cancer targeting regimes which has demonstrated encouraging clinical response in the management of several cancers.
Combination therapy has gained significant popularity among pharmaceutical industry and several companies are actively investing in the segment. To maintain their competitive edge in the global market, companies are developing novel enhanced skills as well as sharing their products to be utilized in combination therapy which can further enhance the efficacy of cancer management. Several large companies including Roche, Pfizer, Merck, Bristol Myers Squibb, Gilead Science, GlaxoSmithKline, Amgen, and others have entered into collaboration or partnership with small ventures to evaluate their drugs in combination therapy.
The regulatory bodies are rapidly giving approval for the novel combination therapy which suggests their promising role and huge research in this sector. For instance in 2022, Europe Commission has granted approval to Keytruda in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced or early-stage triple-negative breast cancer (TNBC) at high risk of recurrence. The approval is based on KEYNOTE-522 trial which demonstrated that the combination prolonged event free survival, thus reducing deaths.
Apart from this, several combination therapies are also awaiting approval which will gain approval in forecast period and drive the growth of market. ImmunityBio has recently submitted biologics license application (BLA) for the first in class cytokine interleukin-15 (IL-15) superagonist, N-803 plus Bacillus Calmette-Guérin (BCG) for the management of patients with BCG-unresponsive non-muscle invasive bladder cancer. Thus, it is expected to gain entry into the market in this year only. ERC Belgium has recently submitted its marketing authorization application (MAA) to EMA for the conditional approval of its lead product SITOIGANAP (ERC1671) to treat recurrent glioblastoma (GBM).
Among all therapeutic drug classes, combination immunotherapy has shown maximum benefits owing to the targeted mechanism of action of immunotherapy across various cancers. The rising adoption of immunotherapy among cancer patients and the promising response of combination therapy over monotherapy are the primary factors propelling the growth of market. Furthermore, it is expected that immune checkpoint inhibitors particularly Keytruda will emerge out to be shining star in the market owing to its role in wide range of cancer and across wide combinations.
Apart from dual combination therapy, it is believed that triple combination therapy will enter the market and is expected to show dominance over dual combination attributing to its ability to target the complex nature of the disease. A preclinical data recently showed that combination of two existing skin cancer drugs and a third experimental drug could lead to a new strategy for treating patients who do not respond to existing therapies. The researchers found that the triple therapy cured 100 per cent of the mice in the study. They hope these findings will feed into future clinical trials looking to improve advanced melanoma skin cancer treatment.
The identification of effective combinations of drug targets generally relies on costly and time consuming processes based on in vitro experiments. However, the advent of enhanced technology like artificial intelligence will bring revolution in significantly lowering the cost as well as time. Recently, scientists have created a prototype test that can predict which drug combinations are likely to work for cancer patients in as little as 24 to 48 hours. Their cutting-edge technique uses artificial intelligence to analyses large-scale protein data from tumor samples, and is able to predict patients’ response to drugs more accurately than is currently possible. The coming years will witness that artificial intelligence will gain traction in the market which is sought to bring big changes in the cancer therapy during the forecast period.
US is expected to dominate the global market during the forecast period. US is an ideal production location for research intensive and high grade products. The country places a high value on technology and it strengths lies in producing complex products where contamination and sterile environments are critical. The countries have hundreds of high-skilled employees in medical-technical, pharmaceutical-technical, and engineering backgrounds which enable pharmaceutical companies to utilize efficient and complex production process. It is analyzed that US has more than 50% of global clinical trials indicating huge potential of combination therapy in this region.
As per our report findings, it is estimated that more than 3000 clinical trials are ongoing in global combination cancer therapy market suggesting future dominance of these in cancer therapeutics market. Our report on global combination immunotherapy market report provides holistic understanding of the market along with market sizing, forecast, drivers, challenges, and competitive landscape. Our report provides comprehensive analysis on the approved combination across various cancers. Apart from this, in-depth analysis on the ongoing clinical trials in novel combinations associated with novel targeted drugs in development by various phases is also mentioned in the report.